2015 to 2021 Saw Marked Rise in PCSK9 Inhibitor Utilization

TUESDAY, March 5, 2024 -- Barriers for proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) use persist for cholesterol management, according to a research letter published online Feb. 16 in Circulation: Cardiovascular Quality and...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news